Latest Breaking News On - நோவர்த்திச் நிறுவனங்கள் க்கு உயிர் மருத்துவ ஆராய்ச்சி - Page 6 : comparemela.com

Share this article Share this article OAKLAND, Calif., June 30, 2021 /PRNewswire/  Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman, today announced the formation of Ancora Bio, a portfolio company developing a new therapy for treatment-resistant depression. Ancora Bio is being formed following the successful in-licensing of a selective vasopressin 1b receptor (V1b) antagonist (ANC-501) from Taisho Pharmaceutical Co., Ltd.    Depression is unfortunately one of the fastest growing mental health challenges, exacerbated by the past 12 months of isolation during the Covid-19 pandemic, said Joe Jimenez, Co-Founder and Managing Director of Aditum Bio. Dr. Mark Fishman, Co-Founder and Chair of the Medical and Scientific Advisory Boards added, ANC-501 has been shown to impact a definable subset of patients with treatment-resistant depression.

John doerrMichael moritzMark fishmanJoe jimenezAncora bioAditum bioNovartis institutes for biomedical researchTaisho pharmaceutical co ltdSequoia capitalNovartis institutesBiomedical researchManaging directorScientific advisory boardsThrive capitalஜான் தோேறுற்மைக்கேல் மோரிட்ஸ்